157 related articles for article (PubMed ID: 36203195)
1. Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer.
Tian X; Wang R; Gu T; Ma F; Laster KV; Li X; Liu K; Lee MH; Dong Z
Mol Cancer; 2022 Oct; 21(1):193. PubMed ID: 36203195
[TBL] [Abstract][Full Text] [Related]
2. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.
Fukuda K; Takeuchi S; Arai S; Kita K; Tanimoto A; Nishiyama A; Yano S
Cancer Sci; 2020 Jul; 111(7):2374-2384. PubMed ID: 32391602
[TBL] [Abstract][Full Text] [Related]
4. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
[TBL] [Abstract][Full Text] [Related]
5. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
6. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
[TBL] [Abstract][Full Text] [Related]
7. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.
Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
Mol Oncol; 2024 Mar; 18(3):641-661. PubMed ID: 38073064
[TBL] [Abstract][Full Text] [Related]
8. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
9. Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.
Roper N; El Meskini R; Maity T; Atkinson D; Day A; Pate N; Cultraro CM; Pack S; Zgonc V; Weaver Ohler Z; Guha U
Cancer Res Commun; 2024 Feb; 4(2):337-348. PubMed ID: 38276867
[TBL] [Abstract][Full Text] [Related]
10. Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
La Monica S; Vacondio F; Eltayeb K; Lodola A; Volta F; Viglioli M; Ferlenghi F; Galvani F; Galetti M; Bonelli M; Fumarola C; Cavazzoni A; Flammini L; Verzè M; Minari R; Petronini PG; Tiseo M; Mor M; Alfieri R
Sci Rep; 2024 Mar; 14(1):6491. PubMed ID: 38499619
[TBL] [Abstract][Full Text] [Related]
11. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.
Romaniello D; Mazzeo L; Mancini M; Marrocco I; Noronha A; Kreitman M; Srivastava S; Ghosh S; Lindzen M; Salame TM; Onn A; Bar J; Yarden Y
Clin Cancer Res; 2018 Nov; 24(22):5610-5621. PubMed ID: 29967248
[No Abstract] [Full Text] [Related]
12. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
[TBL] [Abstract][Full Text] [Related]
13. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC
Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498
[TBL] [Abstract][Full Text] [Related]
14. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.
Liang XM; Qin Q; Liu BN; Li XQ; Zeng LL; Wang J; Kong LP; Zhong DS; Sun LL
Acta Pharmacol Sin; 2021 Apr; 42(4):648-654. PubMed ID: 33414509
[TBL] [Abstract][Full Text] [Related]
17. The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells.
Lee TG; Kang HM; Kim SY; Kim HR; Kim CH
Exp Cell Res; 2023 Sep; 430(1):113722. PubMed ID: 37442265
[TBL] [Abstract][Full Text] [Related]
18. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
La Monica S; Minari R; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Galetti M; Digiacomo G; Riccardi F; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2019 Oct; 14(5):619-626. PubMed ID: 31502118
[TBL] [Abstract][Full Text] [Related]
19. Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.
Sun Y; Dong Y; Liu X; Zhang Y; Bai H; Duan J; Tian Z; Yan X; Wang J; Wang Z
EBioMedicine; 2022 Sep; 83():104200. PubMed ID: 35932642
[TBL] [Abstract][Full Text] [Related]
20. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]